Fusion Pharmaceuticals Inc
NASDAQ:FUSN
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
Price:
21.465 USD
0.07%
Updated:
May 6, 2024
Fusion Pharmaceuticals Inc
Cash from Financing Activities
|
Fusion Pharmaceuticals Inc
Cash from Financing Activities Peer Comparison
Comparables:
ZYME
TH
RPTX
AUPH
EDT
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
|
Cash from Financing Activities
$142m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
Zymeworks Inc
NYSE:ZYME
|
Cash from Financing Activities
$81.8m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Theratechnologies Inc
TSX:TH
|
Cash from Financing Activities
$14.7m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Cash from Financing Activities
$842k
|
CAGR 3-Years
-85%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Cash from Financing Activities
-$5.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Spectral Medical Inc
TSX:EDT
|
Cash from Financing Activities
CA$5.4m
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-1%
|
See Also
What is Fusion Pharmaceuticals Inc's Cash from Financing Activities?
Cash from Financing Activities
142m
USD
142m
USD
Based on the financial report for Dec 31, 2023, Fusion Pharmaceuticals Inc's Cash from Financing Activities amounts to 142m USD.
What is Fusion Pharmaceuticals Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
51%
51%
Over the last year, the Cash from Financing Activities growth was 249%. The average annual Cash from Financing Activities growth rates for Fusion Pharmaceuticals Inc have been -19% over the past three years , 51% over the past five years .
You don't have any saved screeners yet
